Evidence map›Paper›PMID 24618722›Full record

ArticlePloS one2014

Anti-cancer effect of thiacremonone through down regulation of peroxiredoxin 6.

Miran Jo, Hyung-Mun Yun, Kyung-Ran Park, Mi Hee Park, Dong Hun Lee, Seung Hee Cho, Hwan-Soo Yoo, Yong-Moon Lee, Heon Sang Jeong, Youngsoo Kim and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Expression and clinical role ofThe Journal of international medical research · 2024
    Article
  4. Review
  5. Article
  6. Review
  7. Radioprotective Role of Peroxiredoxin 6.Antioxidants (Basel, Switzerland) · 2019
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Miran JoCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Hyung-Mun YunCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Kyung-Ran ParkCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Mi Hee ParkCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Dong Hun LeeCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Seung Hee ChoCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Hwan-Soo YooCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Yong-Moon LeeCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Heon Sang JeongCollege of Agriculture, Life and Environments Science, Chungbuk National University, Chungbuk, Korea.
Youngsoo KimCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Jae Kyung JungCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Bang Yeon HwangCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Mi Kyeong LeeCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Nam Doo KimNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Korea.
Sang Bae HanCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Jin Tae HongCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea.
Chungbuk National University · KRDaegu-Gyeongbuk Medical Innovation Foundation · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thiacremonone (2, 4-dihydroxy-2, 5-dimethyl-thiophene-3-one) is an antioxidant substance as a novel sulfur compound generated from High-Temperature-High-Pressure-treated garlic. Peroxiredoxin 6 (PRDX6) is a member of peroxidases, and has glutathione peroxidase and calcium-independent phospholipase A2 (iPLA2) activities. Several studies have demonstrated that PRDX6 stimulates lung cancer cell growth via an increase of glutathione peroxidase activity. A docking model study and pull down assay showed that thiacremonone completely fits on the active site (cys-47) of glutathione peroxidase of PRDX6 and interacts with PRDX6. Thus, we investigated whether thiacremonone inhibits cell growth by blocking glutathione peroxidase of PRDX6 in the human lung cancer cells, A549 and NCI-H460. Thiacremonone (0-50 μg/ml) inhibited lung cancer cell growth in a concentration dependent manner through induction of apoptotic cell death accompanied by induction of cleaved caspase-3, -8, -9, Bax, p21 and p53, but decrease of xIAP, cIAP and Bcl2 expression. Thiacremonone further inhibited glutathione peroxidase activity in lung cancer cells. However, the cell growth inhibitory effect of thiacremonone was not observed in the lung cancer cells transfected with mutant PRDX6 (C47S) and in the presence of dithiothreitol and glutathione. In an allograft in vivo model, thiacremonone (30 mg/kg) also inhibited tumor growth accompanied with the reduction of PRDX6 expression and glutathione peroxidase activity, but increased expression of cleaved caspase-3, -8, -9, Bax, p21 and p53. These data indicate that thiacremonone inhibits tumor growth via inhibition of glutathione peroxidase activity of PRDX6 through interaction. These data suggest that thiacremonone may have potentially beneficial effects in lung cancer.

Indexed as

AllograftsAnimalsAntineoplastic Agents, PhytogenicApoptosisApoptosis Regulatory ProteinsCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalGarlicGene ExpressionGene Expression Regulation, NeoplasticGenes, ReporterHumansMiceModels, MolecularAntineoplastic Agents, PhytogenicApoptosis Regulatory ProteinsPeroxiredoxin VIPlant ExtractsthiacremononeThiophenes

Identifiers

PMID24618722
PMCPMC3950181
OpenAlexW2010606527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.